$NVO plunges over 20% after slashing 2025 outlook. Weak U.S. demand for Wegovy and compounding competition expose planning and execution failures.

$NVO is still blaming their weakness on ” knockoff GLP1s”😂 I like the company, but why isn’t $LLY doing the same?

Management has to take accountability at some point! pic.twitter.com/sLzJniQLyY

— Patient Investor (@patientinvestt) July 29, 2025

The fall hit hard. Early in the morning Novo Nordisk shares dropped over 20% after slicing its full‑year sales outlook. The core message blames weak U.S. demand for Wegovy and competition from compounded “knockoff” GLP‑1s. On the surface that explains losses but what really unravels underneath is a failure in execution and forecasting paired with strategic missteps.

Outlook cut sharply. Novo now expects 2025 sales growth of 8–14% and operating profit growth of 10–16%. That is down from guidance of 13–21% and 16–24% just months ago. The downgrade triggered a market wipeout, resetting expectations in real time.

The narrative shift also came with a new CEO announcement, accelerating management change. The company named Maziar Mike Doustdar as successor starting August 7. Leadership turnover amid collapse suggests board urgency to restore credibility and control.

Meanwhile, the patient story is this: compounded GLP‑1 versions have proliferated in the U.S. market, cutting into branded Wegovy uptake. Novo blamed compounding providers for undercutting its rollout. But revelations suggest Novo underestimated patient demand for cheaper alternatives. Supply constraints, restrictive insurance coverage, and hesitance to adapt distribution played into that miscalculation.

Beyond that, deep internal warnings reportedly predicted Wegovy’s misalignment: market expansion in the U.S. appeared overestimated, especially against cheaper rivals like Eli Lilly’s Zepbound or Mounjaro. When reality diverged, investors reacted sharply. The mismatch between PR confidence and internal caution shows badly coordinated planning.

The core takeaway is this: the stock drop is not just about knockoffs or slowed demand. It reveals a company caught between ambition and blind spots. Execution failures, poor forecasting, and strategic delays converged into a perfect storm today.

https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugmaker-novo-nordisk-plunges-it-cuts-forecasts-again-2025-07-29/

https://www.reuters.com/sustainability/boards-policy-regulation/how-novo-nordisk-misread-us-market-its-weight-loss-sensation-2025-07-01/

https://www.investors.com/news/technology/novo-nordisk-nvo-stock-lower-guidance-new-ceo/
https://www.ft.com/content/2acf90c7-6b6a-4fd1-87af-63d6a4d64814

https://www.wsj.com/business/earnings/novo-nordisk-stock-earnings-q2-2025-b12fb01c